ELOX (Eloxx Pharmaceuticals) Research & Development: $3.06 Mil (TTM As of Dec. 2025)


ELOX Eloxx Pharmaceuticals Inc ELOX
17 GF Score
Price $12.05
! 1 Warning Sign
View Full Analysis

What is Eloxx Pharmaceuticals Research & Development?

Eloxx Pharmaceuticals ELOX +5.57% 17 Research & Development is $3.06 Mil as of Dec. 2025. GuruFocus rates ELOX with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Eloxx Pharmaceuticals's Research & Development for the six months ended in Dec. 2025 was $3.06 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $3.06 Mil.

Eloxx Pharmaceuticals  (NAS:ELOX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Eloxx Pharmaceuticals Research & Development Related Terms

Eloxx Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Eloxx Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eloxx Pharmaceuticals Research & Development Chart

Eloxx Pharmaceuticals Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.57 23.73 8.60 3.58 3.06

Eloxx Pharmaceuticals Semi-Annual Data
Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.57 23.73 8.60 3.58 3.06
ELOX
17GF Score
Eloxx Pharmaceuticals Inc ELOX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eloxx Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $3.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $3.06 Mil mean?
Eloxx Pharmaceuticals (ELOX) has a Research & Development of $3.06 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Eloxx Pharmaceuticals and its competitors.
Is Eloxx Pharmaceuticals' Research & Development too high?
Eloxx Pharmaceuticals' current Research & Development is $3.06 Mil. Overall, Eloxx Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Eloxx Pharmaceuticals' Research & Development compare to CPMV and OGEN?
Eloxx Pharmaceuticals' Research & Development of $3.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Eloxx Pharmaceuticals and its competitors. Eloxx Pharmaceuticals's current Research & Development is $3.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eloxx Pharmaceuticals stock overvalued right now?
Eloxx Pharmaceuticals (ELOX) has a current Research & Development of $3.06 Mil. The current Research & Development is $3.06 Mil. Eloxx Pharmaceuticals' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Eloxx Pharmaceuticals (ELOX), the current Research & Development is $3.06 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eloxx Pharmaceuticals Business Description

Address 10 Court Street, P.O. Box 274, Arlington, MA, USA, 02476
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
17GF Score

Get the complete analysis for ELOX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.05
Price